Separate names with a comma.
What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts?...
It’s no big secret that investment in biotech stocks can offer great returns for investors, and at the same time, they can do some serious damage...
http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and...
It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today. 1) Celgene acquires Juno for $9 billion...
A trial testing Revlimid on follicular lymphoma did not meet the desired endpoint. Biogen's RITUXAN also fails..